Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex Pharmaceuticals LLC

Division of Vertex Pharmaceuticals Inc.

Latest From Vertex Pharmaceuticals LLC

A Brighter Outlook for New Cystic Fibrosis Drugs

The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.
BioPharmaceutical Business Strategies

Vertex: Sticking To Its Story

Unlike many biotechs, Vertex has consistently cast itself as a product-focused company. To get there, Vertex built a remarkably productive discovery engine that has generated an impressive development pipeline. But to date, the company has produced only one commercial product, an HIV therapy marketed by GSK. That relatively slow path to commercialization is in large part attributable to the company's reliance on its internal R&D to produce drugs. By eschewing the in-licensing path that other biotechs have taken to jumpstart their commercial development, and partnering away commercial rights to a number of its later-stage compounds, the company has left some doubting its commitment to marketing its own drugs. But Vertex is now laying the foundation for creating a full-fledged commercial capability. And if the company can stay on track as it tackles the challenges of integrating a commercial operation into its organization, it may prove the skeptics wrong and accomplish something that perhaps no other biotech has: create a fully integrated pharmaceutical firm on the back of its own R&D.
BioPharmaceutical Strategy

Norak Biosciences Inc.

Norak's founders think that beta-arrestin's movement from within the body of the cell to the membrane-bound receptor is a specific marker of GPCR receptor activation-and their method for watching it all happen in glowing green is the basis of the company's Transfluor technology.
BioPharmaceutical Strategy

Aptus Genomics Inc.

Researchers haven't yet been able to overcome the challenge of isolating and purifying GPCRs from their membrane in a functionally useful form, so it has been difficult to determine their structures, as a starting point for drug discovery. Researchers have, however, developed indirect ways of detecting whether particular compounds activate GPCRs, by measuring the effects of activation. The presence of certain secondary messengers within the cell, for example, calcium or cyclic AMP (cAMP), is a telltale sign that compounds have interacted with GPCRs. Aptus Genomics has applied for a patent for a high-throughput drug screening method for GPCRs that signal through cAMP.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Aurora Biosciences Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vertex Pharmaceuticals Inc.
  • Senior Management
  • John Pashkowsky, VP, Fin.
    Paul J England, PhD, SVP, Research
    Michael Wokasch, Pres.
    William S Ettouati, VP, Bus. Dev.
  • Contact Info
  • Vertex Pharmaceuticals LLC
    Phone: (858) 404-6600
    11010 Torreyana Rd.
    San Diego, CA 92121